Krishna Vaddi

2020

In 2020, Krishna Vaddi earned a total compensation of $11.6M as Chief Executive Officer at Prelude Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$228,667
Option Awards$9,576,741
Salary$417,058
Stock Awards$1,409,998
Total$11,632,464

Vaddi received $9.6M in option awards, accounting for 82% of the total pay in 2020.

Vaddi also received $228.7K in non-equity incentive plan, $417.1K in salary and $1.4M in stock awards.

Rankings

In 2020, Krishna Vaddi's compensation ranked 656th out of 13,090 executives tracked by ExecPay. In other words, Vaddi earned more than 95.0% of executives.

ClassificationRankingPercentile
All
656
out of 13,090
95th
Division
Manufacturing
228
out of 5,621
96th
Major group
Chemicals And Allied Products
73
out of 2,254
97th
Industry group
Drugs
62
out of 1,954
97th
Industry
Pharmaceutical Preparations
46
out of 1,459
97th
Source: SEC filing on April 29, 2022.

Vaddi's colleagues

We found three more compensation records of executives who worked with Krishna Vaddi at Prelude Therapeutics in 2020.

2020

Peggy Scherle

Prelude Therapeutics

Chief Scientific Officer

2020

Andrew Combs

Prelude Therapeutics

EVP and Head of Chemistry

2020

Brian Piper

Prelude Therapeutics

Chief Financial Officer

News

In-depth

You may also like